North China Pharmaceutical Company.Ltd

SHSE:600812 Stock Report

Market Cap: CN¥11.0b

North China Pharmaceutical Company.Ltd Future Growth

Future criteria checks 3/6

North China Pharmaceutical Company.Ltd is forecast to grow earnings and revenue by 48.2% and 5.7% per annum respectively. EPS is expected to grow by 48.5% per annum. Return on equity is forecast to be 4.4% in 3 years.

Key information

48.2%

Earnings growth rate

48.5%

EPS growth rate

Pharmaceuticals earnings growth18.9%
Revenue growth rate5.7%
Future return on equity4.4%
Analyst coverage

Low

Last updated07 Feb 2025

Recent future growth updates

No updates

Recent updates

Insufficient Growth At North China Pharmaceutical Company.Ltd (SHSE:600812) Hampers Share Price

Jan 18
Insufficient Growth At North China Pharmaceutical Company.Ltd (SHSE:600812) Hampers Share Price

Is North China Pharmaceutical Company.Ltd (SHSE:600812) Using Too Much Debt?

Dec 26
Is North China Pharmaceutical Company.Ltd (SHSE:600812) Using Too Much Debt?

Benign Growth For North China Pharmaceutical Company.Ltd (SHSE:600812) Underpins Its Share Price

Sep 25
Benign Growth For North China Pharmaceutical Company.Ltd (SHSE:600812) Underpins Its Share Price

North China Pharmaceutical Company.Ltd's (SHSE:600812) Profits Appear To Have Quality Issues

Aug 20
North China Pharmaceutical Company.Ltd's (SHSE:600812) Profits Appear To Have Quality Issues

The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

Apr 26
The Market Doesn't Like What It Sees From North China Pharmaceutical Company.Ltd's (SHSE:600812) Revenues Yet

Earnings and Revenue Growth Forecasts

SHSE:600812 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202611,0942705861,0811
12/31/202510,4431954559731
12/31/20249,962124N/A1,1131
9/30/20249,706797641,489N/A
6/30/202410,118509481,642N/A
3/31/202410,018187051,403N/A
12/31/202310,12054011,024N/A
9/30/202310,601-6995301,065N/A
6/30/202310,455-6954371,038N/A
3/31/202310,617-6975941,155N/A
12/31/202210,500-6894551,004N/A
9/30/202210,07139407941N/A
6/30/202210,080505821,038N/A
3/31/202210,215905311,045N/A
12/31/202110,385195031,050N/A
9/30/202110,615-28-105732N/A
6/30/202111,158-22-314674N/A
3/31/202111,888-27-267742N/A
12/31/202011,49397-255752N/A
9/30/202012,49522438829N/A
6/30/202012,0432136648N/A
3/31/202011,109208-67582N/A
12/31/201911,45717294764N/A
9/30/201910,160165120737N/A
6/30/20199,827168-35617N/A
3/31/20199,417155174731N/A
12/31/20189,214151268774N/A
9/30/20189,09174343841N/A
6/30/20188,42550N/A857N/A
3/31/20188,01032N/A556N/A
12/31/20177,70919N/A287N/A
9/30/20177,80411N/A32N/A
6/30/20178,12755N/A-113N/A
3/31/20178,09454N/A-448N/A
12/31/20168,08254N/A-447N/A
9/30/20167,64396N/A-377N/A
6/30/20167,36359N/A-322N/A
3/31/20167,91159N/A189N/A
12/31/20157,90363N/A122N/A
9/30/20157,62554N/A265N/A
6/30/20158,31763N/A404N/A
3/31/20158,59550N/A169N/A
12/31/20149,39439N/A94N/A
9/30/201410,95318N/A101N/A
6/30/201411,45915N/A-196N/A
3/31/201412,02215N/A-132N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600812's forecast earnings growth (48.2% per year) is above the savings rate (2.7%).

Earnings vs Market: 600812's earnings (48.2% per year) are forecast to grow faster than the CN market (25.1% per year).

High Growth Earnings: 600812's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600812's revenue (5.7% per year) is forecast to grow slower than the CN market (13.3% per year).

High Growth Revenue: 600812's revenue (5.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600812's Return on Equity is forecast to be low in 3 years time (4.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/17 09:07
End of Day Share Price 2025/02/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

North China Pharmaceutical Company.Ltd is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hongbao ZhangChina Merchants Securities Co. Ltd.
Kai WangCitic Securities Co., Ltd.
null Research DepartmentGuotai Junan International Holdings Limited